What is NanoSyrinx?
NanoSyrinx is an award-winning biotechnology company specializing in the creation of protein nanosyringes designed for the precise intracellular delivery of biologic drugs. Leveraging advanced synthetic biology techniques, the company is tackling the persistent challenge of delivering therapeutic agents, such as antibodies and peptides, effectively to their intracellular targets. Their proprietary platform technology is engineered to unlock cellular interiors, facilitating targeted delivery of protein-based therapeutics and addressing previously undruggable intracellular targets. The company is led by a seasoned management team dedicated to the advancement of biotherapeutics.
How much funding has NanoSyrinx raised?
NanoSyrinx has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$8.5M
Other Financing Round
$13M
Angel/Seed (2021): $8.5M with participation from Merck Ventures
Other Financing Round (2024): $13M led by BGF and Octopus Ventures
Key Investors in NanoSyrinx
Merck Ventures
Merck Ventures is the corporate venture capital arm of Merck, focusing on investments in innovative technologies and products that align with Merck's core business areas. They actively support portfolio companies in translating innovation into commercial success, with a strong emphasis on early-stage investments.
BGF
BGF is a prominent investor in UK small and mid-sized businesses, providing support across various stages of company growth, from early-stage to quoted companies, and operating across all economic sectors.
Octopus Ventures
Octopus Ventures is a venture capital firm that backs mission-driven companies in sectors like software, climate, health, consumer, and financial technology, providing long-term capital and strategic guidance to founders aiming to create global impact.
What's next for NanoSyrinx?
The recent major strategic investment in NanoSyrinx, following its earlier seed funding, indicates the company is likely entering a growth and scaling phase. This capital infusion is expected to accelerate the development and potential commercialization of its protein nanosyringe technology. With a focus on overcoming critical drug delivery hurdles for intracellular targets, NanoSyrinx is poised to make significant contributions to the biopharmaceutical landscape, potentially attracting further strategic partnerships and investment as it progresses through clinical development and seeks to establish its technology as a new standard in targeted therapy.
See full NanoSyrinx company page
